The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
18
03
2020
pubmed:
22
3
2020
medline:
15
5
2021
entrez:
22
3
2020
Statut:
ppublish
Résumé
Taxanes are the current first-line treatment for advanced cutaneous angiosarcoma (CAS) for patients who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. However, no effective second-line therapy for such patients has been established. We designed a single-arm prospective observational study of eribulin mesylate (ERB) administered at a dose of 1·4 mg m We enrolled a total of 25 patients. The median OS and PFS were 8·6 months and 3·0 months, respectively. The best overall RR was 20% (five of 25). In total, 16 grade 3/4 severe adverse events (SAEs) occurred; however, all patients recovered. Patients who achieved partial response or stable disease as best response had longer OS than those with progressive disease (median OS not reached and 3·3 months, respectively; P < 0·001). Patients who did not experience SAEs showed longer OS than those who did (median OS 18·8 months and 7·5 months, respectively; P < 0·05). Patients with distant metastasis had shorter median OS than those with locoregional disease, but without statistically significant difference. ERB showed a promising RR and is a potential candidate for second-line treatment for patients with CAS, after treatment with taxanes. However, owing to the occurrence of SAEs in over half of the participants, caution should be exercised regarding ERB use in elderly patients. What is already known about this topic? Taxanes are the current first-line treatment for patients with advanced cutaneous angiosarcoma (CAS) who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. No effective therapy for taxane-resistant CAS has been established thus far. Eribulin suppresses microtubule polymerization and elicits an antitumour effect similar to that of taxanes. What does this study add? In our single-arm prospective observational study to evaluate the efficacy of eribulin for treating patients with advanced CAS who previously received taxanes, the median overall survival and progression-free survival were 8·6 and 3·0 months, respectively. Response rates at weeks 7, 13 and 25 were 20%, 17% and 14%, respectively. Although 16 grade 3/4 severe adverse events occurred, all patients recovered. Eribulin showed a promising response rate and is a potential candidate for second-line treatment in CAS after taxane treatment. Linked Comment: Smrke and Benson. Br J Dermatol 2020; 183:797-798.
Sections du résumé
BACKGROUND
Taxanes are the current first-line treatment for advanced cutaneous angiosarcoma (CAS) for patients who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. However, no effective second-line therapy for such patients has been established.
METHODS
We designed a single-arm prospective observational study of eribulin mesylate (ERB) administered at a dose of 1·4 mg m
RESULTS
We enrolled a total of 25 patients. The median OS and PFS were 8·6 months and 3·0 months, respectively. The best overall RR was 20% (five of 25). In total, 16 grade 3/4 severe adverse events (SAEs) occurred; however, all patients recovered. Patients who achieved partial response or stable disease as best response had longer OS than those with progressive disease (median OS not reached and 3·3 months, respectively; P < 0·001). Patients who did not experience SAEs showed longer OS than those who did (median OS 18·8 months and 7·5 months, respectively; P < 0·05). Patients with distant metastasis had shorter median OS than those with locoregional disease, but without statistically significant difference.
CONCLUSIONS
ERB showed a promising RR and is a potential candidate for second-line treatment for patients with CAS, after treatment with taxanes. However, owing to the occurrence of SAEs in over half of the participants, caution should be exercised regarding ERB use in elderly patients. What is already known about this topic? Taxanes are the current first-line treatment for patients with advanced cutaneous angiosarcoma (CAS) who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. No effective therapy for taxane-resistant CAS has been established thus far. Eribulin suppresses microtubule polymerization and elicits an antitumour effect similar to that of taxanes. What does this study add? In our single-arm prospective observational study to evaluate the efficacy of eribulin for treating patients with advanced CAS who previously received taxanes, the median overall survival and progression-free survival were 8·6 and 3·0 months, respectively. Response rates at weeks 7, 13 and 25 were 20%, 17% and 14%, respectively. Although 16 grade 3/4 severe adverse events occurred, all patients recovered. Eribulin showed a promising response rate and is a potential candidate for second-line treatment in CAS after taxane treatment. Linked Comment: Smrke and Benson. Br J Dermatol 2020; 183:797-798.
Substances chimiques
Bridged-Ring Compounds
0
Furans
0
Ketones
0
Taxoids
0
taxane
1605-68-1
eribulin
LR24G6354G
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-839Subventions
Organisme : Maruho Takagi Dermatology Foundation
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 British Association of Dermatologists.
Références
Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer 1981; 48:1907-21.
Hodgkinson DJ, Soule EH, Woods JE. Cutaneous angiosarcoma of the head and neck. Cancer 1979; 44:1106-13.
Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol 1998; 22:683-97.
Albores-Saavedra J, Schwartz AM, Henson DE et al. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007. Ann Diagn Pathol 2011; 15:93-7.
Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1948; 1:64-81.
Ravi V, Patel S. Vascular sarcomas. Curr Oncol Rep 2013; 15:347-55.
Depla AL, Scharloo-Karels CH, de Jong MA et al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur J Cancer 2014; 50:1779-88.
Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24:504-14.
Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 1987; 59:1046-57.
Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91:1914-26.
Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008; 113:616-27.
Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26:5269-74.
Pawlik TM, Paulino AF, McGinn CJ et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003; 98:1716-26.
Guadagnolo BA, Zagars GK, Araujo D et al. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 2011; 33:661-7.
Espat NJ, Lewis JJ, Woodruff JM et al. Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma 2000; 4:173-7.
Abraham JA, Hornicek FJ, Kaufman AM et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007; 14:1953-67.
Perez MC, Padhya TA, Messina JL et al. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol 2013; 20:3391-7.
Mizukami S, Taguchi M, Suzuki T, Tsuchida T. Angiosarcoma: a report of 260 patients based on a study conducted by The Japanese Association of Dermatologic Surgery, and review of the literature. Skin Cancer (Japan) 2009; 24:350-62.
Lydiatt WM, Shaha AR, Shah JP. Angiosarcoma of the head and neck. Am J Surg 1994; 168:451-4.
Steward WP, Verweij J, Somers R et al. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. J Cancer Res Clin Oncol 1991; 117 (Suppl. 4):S193-7.
Young RJ, Natukunda A, Litiere S et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer 2014; 50:3178-86.
Di Lorenzo G, Kreuter A, Di Trolio R et al. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol 2008; 128:1578-80.
Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005; 104:361-6.
Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86:2034-7.
Nagano T, Yamada Y, Ikeda T et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 2007; 110:648-51.
Fujisawa Y, Yoshino K, Kadono T et al. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study. Br J Dermatol 2014; 171:1493-500.
Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4:1086-95.
Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377:914-23.
Loprinzi CL, Reeves BN, Dakhil SR et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011; 29:1472-8.
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47.
Fujisawa Y, Yoshino K, Fujimura T et al. Cutaneous angiosarcoma: the possibility of new treatment options especially for patients with large primary tumor. Front Oncol 2018; 8:46.
Fujisawa Y, Nakamura Y, Kawachi Y, Otsuka F. Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience. J Dermatolog Treat 2014; 25:419-23.
Schöffski P, Chawla S, Maki RG et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387:1629-37.
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65.
Kuznetsov G, TenDyke K, Yu M, Littlefield B. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Presented at the AACR-NCI-EORTC International Conference, San Francisco, CA, 22-26 October 2007; abstr. C58.
Ray-Coquard IL, Domont J, Tresch-Bruneel E et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase ii trial. J Clin Oncol 2015; 33:2797-802.
Fayette J, Martin E, Piperno-Neumann S et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007; 18:2030-6.
ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 3):iii102-12.
Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008; 97:74-81.
Kubota N, Fujisawa Y, Nakamura Y et al. Angiosarcoma of the scalp in a patient with systemic sclerosis. J Dermatol 2015; 42:102-4.
Amo Y, Masuzawa M, Hamada Y, Katsuoka K. Serum concentrations of vascular endothelial growth factor in angiosarcomas with and without p53 gene mutation. Acta Derm Venereol 2002; 82:373-4.
Hasenstein JR, Kasmerchak K, Buehler D et al. Efficacy of Tie2 receptor antagonism in angiosarcoma. Neoplasia 2012; 14:131-40.
Koontz BF, Miles EF, Rubio MA et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008; 30:262-6.
De Yao JT, Sun D, Powell AT, Rehmus EH. Scalp angiosarcoma remission with bevacizumab and radiotherapy without surgery: a case report and review of the literature. Sarcoma 2011; 2011:160369.
Rosen A, Thimon S, Ternant D et al. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol 2010; 163:225-7.
Ray-Coquard I, Italiano A, Bompas E et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012; 17:260-6.
Rosen LS, Gordon MS, Robert F, Matei DE. Endoglin for targeted cancer treatment. Current Oncol Rep 2014; 16:365.
Attia S, Sankhala KK, Riedel RF et al. A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). J Clin Oncol 2016; 34 (Suppl.):11016.
Mehta CR, Liu L, Theuer C. An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). Ann Oncol 2019; 30:103-8.
Hodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17:1558-68.
Honda Y, Otsuka A, Ono S et al. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 2017; 6:e1253657.
Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, Phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013; 24:257-63.